Transient ischaemic attack after spacing the dose of alirocumab: Is it advisable to reduce the doses of PCSK9 inhibitors with very low LDL-cholesterols?
Clin Investig Arterioscler. 2020 Jan-Feb;32(1):30-32.
doi: 10.1016/j.arteri.2019.04.003.
Epub 2019 Jun 17.
[Article in
English,
Spanish]
Affiliations
- 1 Departamento de Medicina Interna, Hospital General Universitario Gregorio Marañón, Madrid, España. Electronic address: sandrapqrz@gmail.com.
- 2 Departamento de Medicina Interna, Hospital General Universitario Gregorio Marañón, Madrid, España.
- 3 Unidad de Riesgo Cardiovascular y Lípidos, Departamento de Medicina Interna, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, España.
Abstract
Inhibitors of the protein PCSK9, available since 2015, are capable of reducing the concentration of low density lipoprotein cholesterol by 40 to 70%, thus reducing the cardiovascular risk. The present case reports an adverse cardiovascular event that appeared when spacing out the administration of lipid-lowering treatment. A discussion will be presented on the importance of maintaining low cholesterol levels in order to achieve a greater benefit, according to the latest published clinical studies.
Keywords:
Alirocumab; Cardiovascular events; Evento cardiovascular; Inhibidores de PSCK9; c-LDL; iPCSK9 inhibitors.
Copyright © 2019 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Anticholesteremic Agents / administration & dosage
-
Anticholesteremic Agents / adverse effects
-
Cholesterol, LDL / blood
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Humans
-
Hypercholesterolemia / drug therapy
-
Ischemic Attack, Transient / chemically induced*
-
Male
-
PCSK9 Inhibitors*
Substances
-
Antibodies, Monoclonal, Humanized
-
Anticholesteremic Agents
-
Cholesterol, LDL
-
PCSK9 Inhibitors
-
PCSK9 protein, human
-
alirocumab